Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
US8557847B2 · kind B2 · utility
0Cited by
33References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2009 |
| Grant date | Oct 15, 2013 |
| Priority date | — |
| Expiry date | Nov 12, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′:Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.